Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib (MACS0254)

Novartis

Status and phase

Terminated

Phase 2

Conditions

Chronic Myelogenous Leukemia - Chronic Phase

Treatments

Drug: Nilotinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT00644878

CAMN107AUS09

Details and patient eligibility

About

This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Select Inclusion Criteria:

Male or female patients ≥ 18 years of age with a confirmed diagnosis of Ph+ CML-CP and CCyR
A suboptimal molecular response to imatinib defined as:
- Group 1: Treated with 1 year of imatinib, complete cytogenetic response (CCyR) but no major molecular response (MMR) (Bcr-Abl levels >0.1%IS);
- Group 2: No specific duration of imatinib required, achieved CCyR but has >1 log increase in Bcr-Abl transcript levels
Adequate end organ function
Patients must have had an imatinib washout period of at least 3 days and not to exceed 7 days prior to the first dose of nilotinib. Group 1 patients must have been treated with imatinib for at least 1 year. There was no imatinib treatment duration requirement for Group 2 patients.
For Group 1, patients were eligible for screening if they were treated with an imatinib dose of at least 400mg daily. Dose reduction could have occurred as long as the minimum dose was 300mg daily and the reduction lasted ≤ 28 days. The patient was required to be on 400 mg daily (or a higher dose) of imatinib for at least 6 consecutive months leading up to screening for this study.
For Group 2 patients, dose reduction while on imatinib could have occurred as long as the minimum dose was 300 mg daily, and the reduction lasted ≤28 days.

Select Exclusion Criteria:

Prior accelerated phase or blast crisis CML
Patients achieving prior CCyR on imatinib who lost cytogenetic response prior to entering study
Previously documented T315I mutations
Prior therapy with any other tyrosine kinase inhibitor except imatinib
Patients with contraindications to receiving nilotinib, including concomitant medications